Correlation Between Anebulo Pharmaceuticals and Mineralys Therapeutics,

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Anebulo Pharmaceuticals and Mineralys Therapeutics, at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Anebulo Pharmaceuticals and Mineralys Therapeutics, into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Anebulo Pharmaceuticals and Mineralys Therapeutics, Common, you can compare the effects of market volatilities on Anebulo Pharmaceuticals and Mineralys Therapeutics, and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Anebulo Pharmaceuticals with a short position of Mineralys Therapeutics,. Check out your portfolio center. Please also check ongoing floating volatility patterns of Anebulo Pharmaceuticals and Mineralys Therapeutics,.

Diversification Opportunities for Anebulo Pharmaceuticals and Mineralys Therapeutics,

-0.05
  Correlation Coefficient

Good diversification

The 3 months correlation between Anebulo and Mineralys is -0.05. Overlapping area represents the amount of risk that can be diversified away by holding Anebulo Pharmaceuticals and Mineralys Therapeutics, Common in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Mineralys Therapeutics, and Anebulo Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Anebulo Pharmaceuticals are associated (or correlated) with Mineralys Therapeutics,. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Mineralys Therapeutics, has no effect on the direction of Anebulo Pharmaceuticals i.e., Anebulo Pharmaceuticals and Mineralys Therapeutics, go up and down completely randomly.

Pair Corralation between Anebulo Pharmaceuticals and Mineralys Therapeutics,

Given the investment horizon of 90 days Anebulo Pharmaceuticals is expected to under-perform the Mineralys Therapeutics,. In addition to that, Anebulo Pharmaceuticals is 1.08 times more volatile than Mineralys Therapeutics, Common. It trades about -0.2 of its total potential returns per unit of risk. Mineralys Therapeutics, Common is currently generating about 0.0 per unit of volatility. If you would invest  986.00  in Mineralys Therapeutics, Common on November 29, 2024 and sell it today you would lose (18.00) from holding Mineralys Therapeutics, Common or give up 1.83% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Anebulo Pharmaceuticals  vs.  Mineralys Therapeutics, Common

 Performance 
       Timeline  
Anebulo Pharmaceuticals 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Anebulo Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong technical and fundamental indicators, Anebulo Pharmaceuticals is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors.
Mineralys Therapeutics, 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Mineralys Therapeutics, Common has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fragile performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in March 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Anebulo Pharmaceuticals and Mineralys Therapeutics, Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Anebulo Pharmaceuticals and Mineralys Therapeutics,

The main advantage of trading using opposite Anebulo Pharmaceuticals and Mineralys Therapeutics, positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Anebulo Pharmaceuticals position performs unexpectedly, Mineralys Therapeutics, can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Mineralys Therapeutics, will offset losses from the drop in Mineralys Therapeutics,'s long position.
The idea behind Anebulo Pharmaceuticals and Mineralys Therapeutics, Common pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.

Other Complementary Tools

Fundamental Analysis
View fundamental data based on most recent published financial statements
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Equity Valuation
Check real value of public entities based on technical and fundamental data